Full-Scale Hybrid Effectiveness-Implementation Trials for Mental Health Interventions (R01 - Clinical Trial Required)
Issued by National Institutes of Health · via Grants.gov — US federal funding opportunities
- Published
- 26 Nov 2024
- Closes
- 15 Oct 2027, 23:59 UTC
- Reference
- PAR-25-177
- Location
- United States
- Sector
- Healthcare & Pharma
At a glance
National Institutes of Health in United States has published a funding call in healthcare & pharma: “Full-Scale Hybrid Effectiveness-Implementation Trials for Mental Health Interventions (R01 - Clinical Trial Required)”. Submissions close on 15 October 2027, 369 days from today. Quote reference PAR-25-177 in any correspondence with the buyer. FreeTender has recorded 430 notices from this buyer since 2023, 377 of them currently open. There are 368 open healthcare & pharma notices in United States on FreeTender. Bids are submitted to the buyer through Grants.gov — US federal funding opportunities, not through FreeTender.
Details
Clinical Trials to Test the Effectiveness of Treatment, Preventive, and Services Interventions (R01 Clinical Trial Required). This NOFO is a key element of NIMHs set of NOFOs to support clinical trials research across the intervention development and testing pipeline. The NOFO supports (1) clinical trials to test the effectiveness of optimized therapeutic and preventive interventions for use in community and practice settings; and (2) clinical trials to evaluate the effectiveness of patient-, provider-, organizational-, or systems-level services interventions to improve access, continuity, quality, equity, and/or value of mental health services. This NOFO is intended to support trials that: address a significant problem, such that the findings have potential to inform practice; are adequately powered to definitively answer the primary research question(s), with well-justified hypotheses supported by pilot data; and are designed to examine questions regarding mediators and moderators of effects. Consistent with the NIMH experimental therapeutics approach, this NOFO is intended to support effectiveness trials that explicitly address whether the intervention engages the target(s)/mechanism(s) presumed to underlie the intervention effects (i.e., the mechanism(s) that accounts for changes in clinical/functional outcomes, changes in provider behavior, improved access or continuity of services, etc.). The collaborative R01 mechanism provides support for multisite trials when two or more sites are necessary for completion of the trial (e.g., to increase sample size, accelerate recruitment, or increase sample diversity and representation). Eligibility: Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.
CFDA number(s): 93.242
Federal funding opportunity published on Grants.gov. Applications are submitted through Grants.gov — see the official listing.
Context for bidders
We hold 430 notices from National Institutes of Health, going back to May 2023 — 377 of them still open. They buy mostly in Healthcare & Pharma, Education & Training and Water & Environment. There are 368 open Healthcare & Pharma tenders in United States. This one closes in 369 days.
More from this buyer
- Systematic Characterization of Genomic Variation to Assess Effects of Individual Variants on Genome Function and Phenotype (UM1 Clinical Trials Not Allowed)· closes 14 Dec
- Limited Competition: Stimulating Access to Research in Residency Transition Scholar (StARRTS) (K38 Clinical Trial Not Allowed)· closes 13 Oct
- NIAMS P30 Centers Program (P30 - Clinical Trial Not Allowed)· closes 1 Mar
- Carcinogen Hazard Assessment Monographs Program (CHAMP) (R01 Clinical Trial Not Allowed)· closes 9 Feb
- Computational Modeling and Analysis of the Impact of Genomic Variation on Function (UM1, Clinical Trial Not Allowed)· closes 14 Dec
Similar Healthcare & Pharma tenders
- Apply for Sweetgrass Grants Program (United States)· closes 30 Nov
- Cellular Senescence Network (SenNet): Discovery, Validation Centers (UM1 Clinical Trials Not Allowed)· closes 23 Nov
- IGVF Data and Coordinating Center (U24 Clinical trials Not Allowed)· closes 14 Dec
- Genomic Variant Interactions With Other Variants Or The Environment (UM1 Clinical Trials Not Allowed)· closes 14 Dec
- Neural Ensembles & Used Substances (NExUS) Collaboratory: Building a Multimodal Inventory of Cell Ensembles Encoding the Effects of Addictive Substances (U01 Clinical Trial Not Allowed)· closes 8 Feb
Before you bid on this tender
A quick checklist to help you decide whether to bid and prepare a compliant submission for this healthcare & pharma opportunity. Always verify the details on the official source.
- Confirm the exact closing date and time (and time zone) on the official portal — deadlines are strict and can be revised by a corrigendum.
- Read the full notice and every attached document, including the scope, specifications and any bill of quantities or terms of reference.
- Check the eligibility criteria — prior similar experience, annual turnover, certifications and registrations — and make sure you qualify before investing effort.
- Prepare any earnest-money deposit (EMD) or bid security and the required formats early; missing or wrongly-formatted documents are a common cause of rejection.
- Note how bids must be submitted (online or physical), in what format, and whether a digital signature or portal registration is required.
- Watch for corrigenda and clarifications right up to the deadline — requirements and dates can change.
More Healthcare & Pharma tenders
- Повторный закуп изделий медицинского назначенияРеспубликанское государственное учреждение "Центральный военный госпиталь с поликлиникой Комитета национальной безопасности Республики Казахстан" · Kazakhstan
- О проведении государственной закупки товара для НАО «Казахский национальный медицинский университет имени С. Д. Асфендиярова» способом открытого конкурса — Аппарат искусственного кровообращенияНекоммерческое акционерное общество "Казахский национальный медицинский университет имени С. Д. Асфендиярова" · Kazakhstan
- Public notice regarding procurement of reagents for hematology analyzer at Dr Hedgewar Arogya SansthanHealth & Family Welfare Department, Govt. of NCT of Delhi · India
- услуг по медицинскому освидетельствованиюРеспубликанское государственное учреждение "Служба правительственной связи Комитета национальной безопасности Республики Казахстан" · Kazakhstan
- Изделия медицинского назначенияРеспубликанское государственное предприятие "Больница Медицинского центра Управления Делами Президента Республики Казахстан" на праве хозяйственного ведения · Kazakhstan
FreeTender mirrors this notice for reference. Verify the details and bid on the official portal.
Verify & apply on the official portal →